Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $113.90 | Total: $569.50 |
| 1 | 10 | $96.48 | Total: $964.80 |
| 1 | 25 | $81.74 | Total: $2,043.50 |
| 1 | 50 | $69.68 | Total: $3,484.00 |
| 1 | 100 | $60.30 | Total: $6,030.00 |
Overview
LSD1-IN-27 is a potent LSD1 inhibitor with an IC50 value of 13 nM.LSD1-IN-27 inhibited the stemness and migration of gastric cancer cells.LSD1-IN-27 inhibited the expression of PD-L1 in BGC-823 and MFC cells.LSD1-IN-27 potentiated the T-cell immune response against gastric cancer.
Chemical Properties
| Molecular Formula | C24H25N3 |
| Molecular Weight | 355.48 |
| CAS Numbers | 2904571-94-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(C=1C2=C(N=C3C1C=C(C)C=C3)C(C)=C(C)C=C2)C4=CC=C(N(C)C)C=C4 |
Storage and Handling
0C Short Term, -20C Long Term
References
Dai XJ, et al. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. Eur J Med Chem. 2023 Nov 5;259 115684.